Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan
· Delayed Price · Currency is TWD 46.55
-1.15 (-2.41%)
Jun 13, 2025, 2:32 PM CST
Medigen Vaccine Biologics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 662.47 | 605.64 | 389.62 | 365.04 | 3,281 | 11.51 | Upgrade
|
| Revenue Growth (YoY) | 47.80% | 55.44% | 6.73% | -88.87% | 28413.03% | 927.41% | Upgrade
|
| Cost of Revenue | 235.88 | 209.22 | 159.4 | 577.64 | 975.96 | 3.87 | Upgrade
|
| Gross Profit | 426.58 | 396.42 | 230.22 | -212.6 | 2,305 | 7.64 | Upgrade
|
| Selling, General & Admin | 324.18 | 320.58 | 243.44 | 183.67 | 148.21 | 91.96 | Upgrade
|
| Research & Development | 174.24 | 221.51 | 1,201 | 1,140 | 1,193 | 679.56 | Upgrade
|
| Operating Expenses | 498.42 | 542.09 | 1,444 | 1,324 | 1,341 | 771.52 | Upgrade
|
| Operating Income | -71.84 | -145.67 | -1,214 | -1,536 | 963.73 | -763.88 | Upgrade
|
| Interest Expense | -11.76 | -18.89 | -37.57 | -26.89 | -6.02 | -16.42 | Upgrade
|
| Interest & Investment Income | 45.19 | 46.25 | 83.28 | 7.61 | 2.74 | 1.48 | Upgrade
|
| Currency Exchange Gain (Loss) | 13.38 | 38.35 | -0.33 | 28.86 | 7.52 | 4.15 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.18 | -1.62 | 8.61 | 32.25 | -0.07 | 0.19 | Upgrade
|
| EBT Excluding Unusual Items | -29.21 | -81.57 | -1,160 | -1,494 | 967.9 | -774.49 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.41 | 0.41 | - | - | - | 19.73 | Upgrade
|
| Other Unusual Items | 0.71 | 0.7 | - | 19.86 | 442.36 | 80.54 | Upgrade
|
| Pretax Income | -28.09 | -80.47 | -1,160 | -1,475 | 1,410 | -674.28 | Upgrade
|
| Net Income | -28.09 | -80.47 | -1,160 | -1,475 | 1,410 | -674.28 | Upgrade
|
| Net Income to Common | -28.09 | -80.47 | -1,160 | -1,475 | 1,410 | -674.28 | Upgrade
|
| Shares Outstanding (Basic) | 329 | 329 | 328 | 323 | 319 | 277 | Upgrade
|
| Shares Outstanding (Diluted) | 329 | 329 | 328 | 323 | 321 | 277 | Upgrade
|
| Shares Change (YoY) | 0.06% | 0.10% | 1.50% | 0.73% | 15.82% | 20.08% | Upgrade
|
| EPS (Basic) | -0.09 | -0.24 | -3.53 | -4.56 | 4.42 | -2.43 | Upgrade
|
| EPS (Diluted) | -0.09 | -0.24 | -3.53 | -4.56 | 4.39 | -2.43 | Upgrade
|
| Free Cash Flow | -72.82 | 6.46 | -521.25 | -1,353 | 446.26 | -689.22 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | 0.02 | -1.59 | -4.18 | 1.39 | -2.49 | Upgrade
|
| Gross Margin | 64.39% | 65.45% | 59.09% | -58.24% | 70.25% | 66.36% | Upgrade
|
| Operating Margin | -10.84% | -24.05% | -311.54% | -420.85% | 29.37% | -6638.40% | Upgrade
|
| Profit Margin | -4.24% | -13.29% | -297.68% | -403.95% | 42.98% | -5859.74% | Upgrade
|
| Free Cash Flow Margin | -10.99% | 1.07% | -133.78% | -370.64% | 13.60% | -5989.55% | Upgrade
|
| EBITDA | 48.06 | -26.16 | -1,098 | -1,423 | 1,072 | -653.8 | Upgrade
|
| EBITDA Margin | 7.26% | -4.32% | -281.86% | - | 32.67% | - | Upgrade
|
| D&A For EBITDA | 119.9 | 119.5 | 115.64 | 112.91 | 108.34 | 110.08 | Upgrade
|
| EBIT | -71.84 | -145.67 | -1,214 | -1,536 | 963.73 | -763.88 | Upgrade
|
| EBIT Margin | -10.84% | -24.05% | - | - | 29.37% | - | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.